Selective and brain-penetrant ACSS2 inhibitors target breast cancer brain metastatic cells.
Esquea EM, Ciraku L, Young RG, Merzy J, Talarico AN, Ahmed NN, Karuppiah M, Ramesh A, Chatoff A, Crispim CV, Rashad AA, Cocklin S, Snyder NW, Beld J, Simone NL, Reginato MJ, Dick A.
Esquea EM, et al. Among authors: young rg.
Front Pharmacol. 2024 May 16;15:1394685. doi: 10.3389/fphar.2024.1394685. eCollection 2024.
Front Pharmacol. 2024.
PMID: 38818373
Free PMC article.